லிசா சேசென்ச News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from லிசா சேசென்ச. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In லிசா சேசென்ச Today - Breaking & Trending Today
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner – Consumer Electronics Net consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
Operator Good morning and welcome to the Ocugen conference call. At this time, all participants are in listen-only mode. [Operator instructions] Please note this conference is being recorded. I would now like to turn the conference over to Lisa DeScenza, vice president of integrated communications at LaVoie Health Science to introduce the Ocugen team. You may begin. Vice President of Integrated Communications Thank you, operator. I d like to welcome you to our conference call. With me today are Ocugen s chairman and CEO, Dr. Shankar Musunuri, and our CFO and head of corporate development, Sanjay Subramanian. Earlier this morning Ocugen issued a press release, including a business update and first-quarter 2021 financial results. We encourage listeners to review the press release, which is available on the Ocugen website at www.ocugen.com. This call is also being recorded and a replay will be available on the Investor section of the Ocugen website for approximate ....
and Variant Neutralization Results In April 2021, Ocugen announced that its co-development partner, Bharat Biotech International Limited ( Bharat Biotech ), shared positive results from the second interim analysis of its Phase 3 clinical trial of COVAXIN showing 78% overall efficacy against COVID-19 disease, 100% efficacy against severe COVID-19 disease (including hospitalization), and 70% efficacy against asymptomatic COVID-19 infection, indicating the potential to significantly reduce virus transmission. COVAXIN has additionally demonstrated a remarkable safety profile with several million doses administered to date in India. Moreover, in-vitro studies conducted by the Indian Council of Medical Research-National Institute of Virology have provided data suggesting effectiveness in neutralizing the double mutant India variant, the U.K. variant, and the Brazil variant. Based on broad immunogenicity, Ocugen believes that COVAXIN has the potential to be effective against other eme ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ocugen announces studies showing COVAXIN potentially effective against three key variants of . OcugenMay 3, 2021 GMT Potential effectiveness against multiple variants reduces the possibility of mutant virus escape According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at least 17 countries MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also s ....
Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2 COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant Potential effectiveness against multiple variants reduces the possibility of mutant virus escape According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at least 17 countries MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also sugges ....